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The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of 
naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the 
initial treatment. However, populations have been defined that respond less well to routine treatment including African 
Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched 
in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact 
treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-
responders in general. Early viral kinetics can be used to define response or non-response and these results can be used 
to modify subsequent treatment length and dose. 
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1.  Introduction 
In the treatment of HCV, the benefits of peg 
interferon alpha and ribavirin have become clear over the 
past decade. Where on one hand, this treatment has 
proven its effectiveness in ideal population; it has also 
identified some special populations by way of poor 
response or difficulties faced due to co morbid conditions.  
These special populations include patients with cirrhosis, 
non responders to prior treatment, HIV positive patients, 
patients with African American ethnicity, steatosis, and 
post liver transplants.     
2.  Viral Kinetics.  
Active viral replication in hepatocytes is a hallmark 
of HCV infection.  However, it is likely that viral auto-
regulation [1] as well as immune factors [2] are important 
in the control of this infection.  Viral auto-regulation is 
demonstrated by the lack of unlimited viral replication in 
patients with inhibited immunologic systems and by 
decrease in the viral RNA level before the emergence of a 
significant immune response in acute disease [1]. 
Immunologic factors are important as recovery from acute 
viral hepatitis is associated with an unopposed TH1 
response exposed to HCV and is also enhanced following 
treatment, associated with a sustained virologic response 
(SVR) in Chronic HCV [3]. In general, immune factors 
prior to treatment or early in treatment do not predict 
sustained viral response (SVR), defined as negative serum 
test for HCV RNA 6 months after completion of therapy. 
Immune factors may be of major importance once the viral 
load has been sufficiently reduced so that hepatocytes 
containing the virus are destroyed. The viral kinetic 
profile (the decrease in viral RNA level with time) in 
response to treatment can be biphasic or triphasic in the 
first 4 weeks of treatment. The final phase slope seems to 
be the most important in determining SVR perhaps 
related to the death of viral infected hepatocytes [4, 5]. A 
very early virologic response (VEVR) having a negative 
RNA at week 4 correlates with the likelihood of an SVR 
[5]. Recent studies have shown that viral reduction in the 
blood in the first 2-4 weeks precedes the immunologic 
response and may reflect viral reduction below a 
threshold that allows effective immune attack of infected 
cells [3]. Furthermore, the mutagenic effect of ribavirin on 
the NS5A and NS5B regions correlates with an SVR 
emphasizing the importance of viral factors [6]. Therefore, 
viral reduction may allow immune clearance rather than 
immune enhancement causing viral clearance.  
HCV patients can be divided into rapid and slow 
responders based on viral kinetics (Table 1) [4]. Forty 
percent of patients were slow responders in one study and 
this correlated with a positive HCV RNA levels in blood 
at week 4. A negative 4 week viral RNA level is sensitive 
(95%) and relatively specific (83%) marker for viral kinetic 
fast responders [4]. Most patients with a fast response 
characterized by negative week 4 viral RNA will have an 
SVR (90%) regardless of genotype [4, 7]. This implies that 
some populations may be treated for short periods of time 
i.e. 4 months for genotype 2 and 3 [8] and 6 months for 
genotype 1 [9] depending upon their response to 
treatment and viral load. Where a negative viral RNA at 
week 4 predicts an SVR, lack of an early virologic 
response (EVR), which is defined as a minimum of 2 log 
decrease in viral load at week 12 of treatment, predicts a 
non-response with more than 97% accuracy [5]. Lack of an 
EVR is an indication that treatment can either be stopped 
or dose increased. Kinetic analysis also suggests the value 
of longer treatment if the RNA level becomes negative 
after 12 weeks [10]. 
 TABLE 1. Viral Kinetics Predict SVR 
  Week 4 RNA  Week 12 RNA  End of 
Treatment 
SVR 
VEVR  Negative  Negative  Negative  90 % * 
EVR  Positive  Negative or < 
1/100 baseline 
Negative  70 % ** 
*May shorten treatment course in genotype 2 to 4 months or genotype 1 with 
LVL to 6 months with same SVR (8, 9) Int. J. Med. Sci. 2006, 3  70
**May lengthen treatment by 3 to 6 months if 12 week RNA still positive to 
have an increased likelihood of an SVR. 
3.  Treatment in African Americans 
Prevalence of HCV in African Americans is about 3 
times greater than Caucasians [11]. The problems of HCV 
infected African Americans are that they are more likely 
to be infected with genotype 1, more likely to have HCV 
complications, have higher rate of cirrhosis, HCC and 
death due to HCV[12]. 
The 4 week log reduction in viral RNA was seen to 
be less in African Americans than Caucasians by 50%. 
This indicates a larger population of slow responders in 
African Americans which may explain a low SVR in this 
population compared to other groups [13]. African 
American patients showed significantly lower decrease in 
HCV RNA over the first 24 hours than Caucasians and 
significantly longer delay in initial response and 
significant difference in the rate of loss of virus producing 
cells [13].  Various studies have ruled out other 
explanations including lack of adherence and dose 
reduction due to poor tolerance or low baseline 
neutrophils, for the poor response. In fact, a larger 
percentage of African Americans completed the therapy 
in some of these studies compared to other racial groups 
despite a greater reduction in neutrophils as anticipated 
with the low baseline levels [13]. Despite greater 
compliance and similar side effect profile, the SVR was 
decreased in African Americans relative to other groups 
[11]. Regardless, combination therapy with interferon 
alpha and ribavirin remains the treatment of choice for 
African Americans with chronic HCV [11].  
The lack of suppression by treatment should be 
amendable to higher dose treatment or prolonged therapy 
once viral suppression is adequate. Though this has not 
been studied directly in the African American population, 
it has been studied in non responders and relapsers to 
prior monotherapy. 
4.  Immune Suppressed Populations – post liver 
transplant or HIV infection   
Immune suppressed patients have a higher baseline 
RNA level and more rapid progression to cirrhosis [14, 
15]. The increase in RNA level supports the importance of 
what appears to be a relatively weak, ineffective immune 
response since it is inadequate to clear the virus. Since 
immunologic mediated inflammation is thought to be the 
mechanism of progressive fibrosis, it is surprising that 
immune suppression does not ameliorate the disease at 
the expense of higher viral levels. The exact relationship of 
immune suppression to progression of fibrosis is unclear, 
but suggests there may be a differential effect on 
lymphocyte sub-populations [16, 17, 18].  
In HIV positive patients with HCV, the rate of 
fibrosis and rate of progression to cirrhosis or 
decompensation (RR=2.92, 95% CI 1.70-5.01) is markedly 
increased particularly with reduced CD4 counts [19]. 
Chronic liver disease has become the most common cause 
of death in adequately treated HIV patients [20]. Evidence 
for more rapid progression can also be found in HCV 
patients with recurrence after liver transplant with > 10 % 
having cirrhosis within 5 years [18, 21]. Patients 
transplanted for HCV eventually have significantly 
reduced survival relative other transplant groups 
primarily related to recurrent cirrhosis. 
The treatment of these two immunologically 
suppressed cohorts are complicated since both are on 
multiple drugs with potential for interactions or 
hepatotoxicity and which may have independent effects 
on bone marrow suppression. Close monitoring is 
required along with treatment of cytopenias, dose 
reduction, and dose discontinuation (20-30%) in the 
management of these patients. Interferon monotherapy 
and interferon alpha 2b plus ribavirin have low response 
rates (10-30 % and 20-30%, respectively) [15]. Pegylated 
interferons plus ribavirin (usually in reduced dose of 800 
mg/day) have higher response rates than these latter two 
options (30-45%) [15]. The early viral kinetics in these 
patients is similar to unsuppressed patients with higher 
viral loads baseline. The lack of EVR is equally predictive 
of NR (98%) allowing a decision to stop treatment if this 
criteria is not met [15].  
5.  Cirrhotics 
Treatment of non-decompensated cirrhotics is 
important since they have reduced survival, increased 
incidence of HCC and progression to a decompensated 
state with ascites and GI bleeding [19]. The goal of therapy 
is to prevent progression of liver disease to these poor 
clinical outcomes. An SVR has been shown to reduce these 
unfavourable outcomes by at least 50 %, but even a 
treatment course without a durable virologic response 
appears to reduce these complications [13, 20]. These latter 
studies have led to clinical protocols of low dose 
maintenance treatment in which the goal of therapy is 
changed from viral cure to prevention of disease 
progression. Clearly, treatment is strongly indicated with 
early cirrhosis without decompensation as progression 
will occur in the majority of patients. Treatment is more 
difficult in the setting of decompensated cirrhosis 
although this can produce an SVR in 20-25% of patients 
[22]. 
The SVR for naïve compensated cirrhotic patients is 
30-45% compared to 50-55% in non-cirrhotics. Potential 
explanations for the reduced SVR could be inherently 
poor virologic response with a decrease in the week 4 
reduction and intolerance of treatment requiring dose 
reduction. Clearly, genotype 2 or 3 and low viral load 
predict better results [23]. In a small study, cirrhotics did 
not have slow response characteristics which predict non- 
response. The major problem appears to be relapse once 
medication is stopped. These patients may respond to 
longer treatment once the viral levels have become 
negative although this has not been studied.  
Retreatment of cirrhotics with pegylated interferon 
and ribavirin is also associated with a poor SVR (6-12%) 
[23]. A low response was found in the retreatment with 
pegylated alpha 2a plus ribavirin in cirrhotics (12% SVR) 
compared to non-cirrhotics (20% SVR) in lead in phase of 
the HALT-C trial [23]. The initial publication from this 
trial concluded that ribavirin dose reduction affected the 
SVR more than interferon reduction [23] although dose 
discontinuation was lumped together with dose 
reduction. Subsequent analysis showed that patients with 
dose continuation (primarily ribavirin) had virtually no 
SVR (1.3%). In the rest, ribavirin reduction to < 60% of 
target dose did not affect SVR (17%) as long as pegylated 
interferon dose was not reduced.  
These patients were further divided into 4 cohorts of 
liver disease severity based on the histologic cirrhosis and 
platelet count < or > 125,000 cell/mm3 [24]. Those in the Int. J. Med. Sci. 2006, 3  71
best cohort (non-cirrhotic with platelets > 125,000 
cells/mm3) had an SVR of 17% compared to 7-8% in the 
cirrhotic groups. In the non-cirrhotic patients, dose 
reduction (without discontinuation) had no impact on the 
SVR whereas there was a nearly significant effect in 
cirrhtoics (12 % with full dose vs 7-8% for dose reduction; 
p = .058). Further support for liver disease severity being 
the most important factor in the non-response of cirrhotic 
patients was provided in an ancillary study of 
quantitative liver functions tests that included cholate 
shunt and clearance, perfused hepatic mass (PHM) by 
quantitative liver spleen scan, and aminopyrine breath 
test showed that the most severe quartile of these patients 
had an SVR of 2% compared to 17% in the other quartiles 
[25]. Severity of liver disease impacts response to 
treatment directly rather than primarily through dose 
reduction or intolerance. 
6.  Fatty Liver 
Fatty liver predicts a lower SVR regardless of other 
factors in both primary treatment (SVR 40-50 % vs 50-55% 
without steatosis) and re-treatment of non-responders 
w i t h  p e g y l a t e d  i n t e r f e r o n  p l u s  r i b a v i r i n  ( S V R  1 0 - 2 0  %  
with vs 20-30 % without) [26]. In pegylated interferon 2b, 
weight based dosing have been suggested as an important 
factor. Weight based dosing is dependent on 
pharmokinetics. It is required for Pegylated alpha 2b and 
not for alpha 2a. There is a decrease in SVR in patients 
with a fatty liver to a similar degree with both products 
using the recommended doses [27]. The weight based 
dosing with Peg alpha 2b does not produce better results 
in patients with fatty liver. 
7.  Re-treatment of non-response 
Naïve patients initially treated with interferon 
monotherapy have a low response rate that is improved 
by longer treatment from 24 to 48 weeks [28]. Re-
treatment with peginterferon plus ribavirin will produce 
SVR of 28% [23]. Even patients initially treated with 
pegylated interferon monotherapy have a 20% SVR to re-
treatment with pegylated combination therapy [29]. 
Therefore, re-treatment with peginterferon plus ribavirin 
should be considered in non-responders or relapsers to 
interferon monotherapy. 
The effect of longer treatment as a principal can be 
seen in the initial studies with interferon monotherapy in 
which the SVR increased from 6% with 6 months of 
treatment to 12% with 12 months [5, 30]. Additional 
evidence comes in the studies of patients treated with PEG 
interferon plus ribavirin for 6 months with relapse, who 
were then treated for 12 months with a 50% SVR. Those 
people with viral suppression during treatment may 
benefit from stronger and longer treatment [5].  
Table 2 shows the SVR in re-treatment of patients 
who were non-responders to combination therapy with 
regular interferon and ribavirin. The SVR ranges from 4-
12 %with responses greater with genotypes 2 and 3. The 
effect of longer treatment has not been tested. Non-
responders to Peg-interferon plus ribavirin have 
exhausted our routine relatively tolerable therapy. 
However, dose induction studies attempt to maximize 
viral RNA suppression by early higher dose treatment 
protocols which are often somewhat longer as well. 
Protocol includes ribavirin plus peginterferon alpha 2a at 
270 or 360 µg per week and consensus interferon with 27, 
18 and 9µg daily [31]. 
TABLE 2.  Retreatment of IFN +  RBV failures with PEG-IFN 
+ RBV 
Investigator  Patients   Study Drug/Dose  SVR 
Teuber G, et al. DDW. 
2003 
240 PEG-IFN  α-2b 
100µg + RBV 800 
mg x 8wk, PEG-
IFN α-2b 50 µg + 
RBV 800 mg x 40 
wk 
6.3% 
Jacobson I, et al. 
DDW 2003 
219 PEG-IFN  α-2b 1.0 
µg/kg  + RBV 1-
1.2g x 48 wk, 
PEG-IFN α-2b 1.5 
µg/kg + RBV 800 
mg x 48wk 
6% 
10% 
Sulkowski M, et al. 
DDW 2003 
517 PEG-IFN  α-2b 1.5 
µg/kg + RBV 
800mg x 48 wk, 
PEG-IFNα-2b 
100/150 µg + RBV 
800 mg x 48 wk 
12% 
Lawitz E, et al. DDW 
2003 
486 PEG-IFN  α-2b 1.5 
µg + RBV 800 mg 
x 48 wk, PEG-IFN 
α- 2b 1.0 µg/kg + 
RBV 800 mg x 
36/48 wk 
5-10% 
Gross JB et al, AASLD 
2003 
764 PEG-IFN  α 2b 
0.5/1.5/3 µg/kg 
RBV 12-15 mg/kg 
x 48 wk 
4-11% 
Shiffman ML et al 
Gastroenterology 
2004 
210 PEG-IFN  α 2a 180 
µg + RBV 1-1.2 g x 
48 wk  
12% 
 
Re-treatment has not been investigated directly in 
large numbers of patients with co-infection, fatty liver or 
cirrhosis. However, the non-responder re-treatment trials 
are enriched with these patients as are the lead-in phase of 
the some of the maintenance studies. Furthermore, some 
trials now define non-responder as early as 12 or even 4 
weeks modifying treatment with either stronger treatment 
or longer treatment to try to produce a better SVR [7, 32].  
8.  Longer treatment 
Kinetic studies suggest potential value for large 
treatment in patients who slowly become RNA negative, 
particularly in genotype 1 patients [10]. A study by 
Sanchez-Tapias et al [7] treated patients with a pegylated 
alpha 2a plus ribavirin (1000 or 1200 mg ) for 4 weeks. 
Preliminary data in abstract form showed those  patients 
that have a negative RNA by PCR  ( 40% of cohort) 
continued treatment for either 6 or 12 months depending 
on genotype with SVR of 92%. Those patients who were 
RNA positive were randomized to either a total of 48 
weeks or 72 weeks followed by RNA levels 6 months after 
stopping with SVR of 35 and 50 % respectively (p<.001). 
Slower responders benefit from longer treatment. 
9.  Stronger treatment 
Induction studies have treated patients with non-
response and relapse with higher  
Doses of Consensus or pegylated interferons for the 
first 1-12 weeks followed by continued high dose or return 
to more normal treatment regimes. Retreatment under a 
variety of protocol conditions have achieved SVR from 25-
40% in patients with expected response rates of 1-12%. 
Most of the results from these very interesting studies are 
published in abstract form and we are waiting the 
publication of the full articles. 
A study by Kaiser, et al [31] of induction dosing with 
daily Consensus interferon and Ribavirin (11 mg/kg/day) 
starting after week 4. Thirty patients in group A received Int. J. Med. Sci. 2006, 3  72
27 ug SC daily for 4 weeks followed by 18 ug daily for 12 
weeks and the second group B of 30 patients received 9 ug 
SC daily for 16 weeks. At the end of 16 weeks, all patients 
were treated with 9 ug SC daily until the patient had been 
HCV RNA negative for 48 weeks. RNA was negative at 24 
weeks in 47% and 40%, respectively, and at the end of 
treatment in 50% and 43%. The SVR was 27% in group A 
and 23% in group B. Adverse events, dose discontinuation 
(10 vs 3%) and dose reduction (23 vs 10%) were similar to 
conventional therapy. All patients were treated longer 
than 48 weeks (if treatment was not stopped) and the 
average was 60 weeks. 
One study by Leevy, et al [33] treated patients with 
peg interferon alpha 2b (1.5 ug/kg weekly) and weight 
based ribavirin (1000-1200 mg per day) for 3 months.   
Patients without an EVR were then treated with 
consensus interferon 15 ug daily for 3 months followed by 
15 ug TIW for the remainder of treatment for a total of 15 
months of treatment. RNA negativity at 12, 24 and 48 
weeks was 23, 31 and 43 %. SVR was 37 % overall and 27 
% in AA compared to 41% in non-AA. This study mimics 
the situation in clinical practice in which failure during 
therapy is followed by the decision to treat with higher 
dose or to stop treatment as ineffective. Despite fatigue 
and tiredness in nearly all patients and a decrease in ANC 
to < 750 cells/mm3 in 22 %, no patients stopped 
treatment. 
A small study (75 patients) by Diago et al [34] 
assessed induction dose with pegylated interferon alpha 
2a in three cohorts of genotype 1 patients who were non-
responders to regular interferon alpha 2b plus ribavirin. 
All patients were treated for 44 weeks with 180µg 
pegylated alpha 2a and ribavirin after an initial 4 week 
induction dose of 180, 270 360µg per week ( total 
treatment of 48 weeks). The SVR was 18%, 30% and 38% 
in the respective groups. Gitlin et al [35] reported results 
in patients with non-response to pegylated alpha 2b plus 
ribavirin. The SVR in response to retreatment with 
pegylated alpha 2a plus ribavirin was 32% overall with 
27% in cirrhotics and 14% in African Americans. 
The results of RENEW trial of induction dosing using 
pegylated alpha 2b plus ribavirin in 650 interferon alpha 
2b plus ribavirin non-responders were less encouraging. 
The SVR to 0.5µg/kg, 1.5µg/kg and 3µg/kg was 4%, 7% 
and 11% respectively [36]. However, the TARGET trial of 
3.0µg/kg  of pegylated alpha 2b plus ribavirin showed 
SVR of 14% [37]. 
In conclusion, higher dose and induction dosing 
seems to produce acceptable salvage SVR in patients who 
are non-responders to prior combination therapy. 
10. Recommendations 
In naïve patients in special populations, the 
treatment can be started off with regular dose of 
pegylated interferon and weight based dosing for 
ribavirin. However, since these populations in general 
have a lower response rate, it seems reasonable to modify 
dosage or length of treatment based on 4th and 12th week 
viral RNA level. Patients with genotype 2 or 3 and 
genotype 1 with low viral load who became negative for 
viral RNA at week 4 , may have a shorter length of 
treatment of 4 months and 6 months respectively without 
sacrificing the SVR. 
In patients who are RNA positive at week 4 and do 
not meet the EVR criteria at week 12, then the treatment 
can be stopped or considered for dose escalation with 
pegylated interferon or daily dosing with infergen. If Viral 
RNA is positive at week 4 but meets EVR at week 12, 
medication should be continued. If HCV RNA by PCR is 
not negative by month 6, then treatment can be stopped or 
considered for dose escalation. But if it does become 
negative by month 6, it seems reasonable in this group of 
difficult to treat patients to treat for 72 months total as 
long as RNA remains negative. The role of maintenance 
treatment in these special groups of non-responders is not 
clear, but should be considered in those with moderate 
fibrosis or cirrhosis. 
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Figure 1. Approach to the Chronic Hepatitis C Treatment in difficult to treat patients 
 